SCHEMBL13101040

SCHEMBL13101040

Nc1cncc(NCc2ccsc2)n1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.45
PNP P00491 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
PTGS2 P35354 2/20 0.40
DYRK1A Q13627 2/20 0.40
FYN P06241 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
PIM1 P11309 1/20 0.38
DYRK2 Q92630 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
MCHR1 Q99705 3/20 0.37
TLR7 Q9NYK1 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
SCN5A Q14524 4/20 0.35
SCN9A Q15858 4/20 0.35
KCNH2 Q12809 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13101047 0.78 FYN (0.59) FYNSCN5ASCN9A
SCHEMBL13101037 0.74 MEN1 (0.58) KDM4CFYN
SCHEMBL14869591 0.72 CA1 (0.49) NPC1PNPKDM4CPTGS2DYRK1A
SCHEMBL454284 0.70 NPC1 (0.67) NPC1PNPKDM4CPTGS2DYRK1A
Hydrochloric Acid SCHEMBL6297807 0.69 NPC1 (0.70) NPC1PNPKDM4CDYRK1AADORA3
SCHEMBL5042272 0.68 SCN9A (0.41) SCN5ASCN9AKCNH2
SCHEMBL28509025 0.67 CXCR4 (0.66) NPC1KDM4C
SCHEMBL14394066 0.67 FYN (0.49) NPC1PNPKDM4CFYNADORA3
SCHEMBL15100791 0.67 PIM1 (0.45) NPC1PNPDYRK1AADORA3ADORA2A
SCHEMBL14869666 0.67 CA1 (0.46) NPC1PNPKDM4CPTGS2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458115-B2 Synthesis of substituted pyrazines LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) 2016-10-04 US disclosed
US-20100267955-A1 SYNTHESIS OF PYRAZINES INCLUDING 2,6-DIAMINOPYRAZINE-1-OXIDE (DAPO) AND 2,6-DIAMINO-3,5-DINITROPYRAZINE-1-OXIDE (LLM-105) ENERGY, U.S. DEPARTMENT OF 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267955-A1 SYNTHESIS OF PYRAZINES INCLUDING 2,6-DIAMINOPYRAZINE-1-OXIDE (DAPO) AND 2,6-DIAMINO-3,5-DINITROPYRAZINE-1-OXIDE (LLM-105) DAO, ADH5, LEO1 NPC1 4701/4885PNP 493/4885KDM4C 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.